PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Texas Children\'s Hospital Center for Vaccine Development, Houston, TX, USA.\', \'Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.\', \'Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.\', \'Department of Biology, Baylor University, Waco, TX, USA.\', \'James A. Baker III Institute for Public Policy, Rice University, Houston, TX, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/21645515.2021.1901545
?:doi
?:hasPublicationType
?:journal
  • Human vaccines & immunotherapeutics
is ?:pmid of
?:pmid
?:pmid
  • 33847226
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all